IP Library Granted Patent US 7,682,607
Granted Patent B2
US 7,682,607 · App. 10/381,636 · Granted Mar 23, 2010

Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,682,607
App. No.
10/381,636
Granted
Mar 23, 2010
Kind
B2
Abstract

The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt/Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the growth and survival of a subset of HNSCC may depend on the Wnt/Fzd pathway. Therefore, The Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.

Claims (6)

1. A method of inhibiting the proliferation or survival of head and neck squamous cell carcinoma cells that require overexpression of a Wnt-1 protein in a Wnt/zd signaling pathway for proliferation or survival, wherein the carcinoma cells overexpress the Wnt-1 protein when compared to non-carcinoma cells of the same cell type, said method comprising contacting the carcinoma cells with an anti-Wnt-1 antibody that inhibits the Wnt/zd signaling pathway in the carcinoma cells.

2. The method according to claim 1 , wherein the anti-Wnt-1 antibody is an antagonist of the Wnt/zd signaling pathway.

3. A method of inhibiting the proliferation or survival of head and neck squamous cell carcinoma cells that overexpress a Wnt-1 protein when compared to non-carcinoma cells of the same cell type, said method comprising contacting the carcinoma cells with an anti-Wnt-1 antibody that facilitates carcinoma cell toxicity or killing by complement.

4. A method of inhibiting the proliferation or survival of head and neck squamous cell carcinoma cells that overexpress a Wnt-1 protein when compared to another Wnt protein in the same carcinoma cells, said method comprising contacting the carcinoma cells with an anti-Wnt-1 antibody that facilitates carcinoma cell toxicity or killing by complement.

5. A method of inhibiting the proliferation or survival of head and neck squamous cell carcinoma cells, that require overexpression of a Wnt-1 protein in a Wnt/zd signaling pathway for proliferation or survival, wherein the carcinoma cells overexpress the Wnt-1 protein when compared to non-carcinoma cells of the same cell type and wherein the Wnt-1 protein is overexpressed when compared to another Wnt protein in the same carcinoma cells, said method comprising contacting the carcinoma cells with an anti-Wnt-1 antibody that inhibits the Wnt/zd signaling pathway in the carcinoma cells.

6. The method according to claim 5 , wherein the anti-Wnt-1 antibody is an antagonist of the Wnt/zd signaling pathway.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 13, 2011
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027054/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2004
From: RHEE, CHAE-SEO; SEN, MALINI; WU, CHRISTINA; LEONI, LORENZO M.; CORR, MARIPAT; CARSON, DENNIS A.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 015464/0512 →
Continuity (2)
Provisional Application 6028799500 · May 1, 2001
Related Publication 20040203003A1 · Oct 14, 2004